Phase 4 Vasculitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with Takayasu Arteritis (TAK) using recognized medical classification guidelines
- You are a man or woman between 18 and 65 years old
- You agree not to try to become pregnant (or father a child) during the trial, and if you are a woman, your pregnancy test must come back negative before joining
- Your Takayasu Arteritis is currently considered active, based on a standard set of disease activity measures
- You are willing to read and sign a consent form agreeing to take part in the trial
Who may not be able to join:
- You have serious organ problems, such as severe heart failure, significantly reduced kidney function, moderate-to-severe liver disease, frequent fainting/blackout episodes (3 days in a row), a recent stroke or brain bleed, or blood pressure higher than 160/100 mmHg
- You have had major blood vessel surgery related to TAK in the last 3 months, or any other blood vessel procedure or surgery (unrelated to TAK) in the last month
- You have another autoimmune disease, such as lupus, Behcet's disease, or a related blood vessel condition
- You have another serious, worsening, or hard-to-control illness affecting your kidneys, liver, blood, gut, lungs, or heart that could put you at extra risk
- You have a condition like asthma that may require you to take medium-to-high doses of steroid medication during the study
- You currently have an active infection such as hepatitis B, hepatitis C, tuberculosis, or another serious ongoing infection
- You have or have had cancer
- Your recent blood test results show certain abnormalities, such as raised liver enzymes, low white blood cell count, low platelets, low hemoglobin (anaemia), or other results that could put you at risk (confirm with trial site)
- You are allergic to the study drug being tested
- You have previously tried the medications tofacitinib or methotrexate for at least 3 months and they did not work for you
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lindi Jiang, Ph.D., M.D., Department of Rheumatology in Zhongshan hospital, Fudan University
Phone: 021-64041990
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The effectiveness rate after 6 months' treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.